Literature DB >> 11981797

Catheter-directed thrombolysis for lower extremity deep vein thrombosis.

M W Mewissen1.   

Abstract

The elimination of the embolic potential of existing thrombus, the restoration of unobstructed flow, the prevention of further thrombosis, and the preservation of venous valve function are the ideal goals of therapy for acute deep vein thrombosis (DVT). Meeting these goals will not only prevent pulmonary embolism but will also minimize the long-term sequelae of venous hypertension and the development of postthrombotic syndrome (PTS). Treatment strategies aimed at eliminating or reducing the risk of PTS should focus on preserving valvular function and eliminating the risk of continued venous obstruction after acute DVT. Thrombolytic agents are an attractive form of early therapy because they have the ability to eliminate obstructive thrombus in the deep veins and should therefore help provide protection against PTS. The perceived benefits of early and rapid recanalization in preserving valve function has been the basis for the use of lytic therapy to treat acute DVT. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11981797     DOI: 10.1016/s1089-2516(01)90005-8

Source DB:  PubMed          Journal:  Tech Vasc Interv Radiol        ISSN: 1557-9808


  5 in total

1.  Acute renal failure associated with percutaneous mechanical thrombectomy for iliocaval venous thrombosis.

Authors:  Bulent Arslan; Ulku Cenk Turba; Alan H Matsumoto
Journal:  Semin Intervent Radiol       Date:  2007-09       Impact factor: 1.513

2.  Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution.

Authors:  Nicholas A Dewyer; Vikram Sood; Erin M Lynch; Catherine E Luke; Gilbert R Upchurch; Thomas W Wakefield; Steven Kunkel; Peter K Henke
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

3.  (18)F-FDG PET in the evaluation of acuity of deep vein thrombosis.

Authors:  Matthew T Rondina; Uyen T Lam; Robert C Pendleton; Larry W Kraiss; Nathan Wanner; Guy A Zimmerman; John M Hoffman; Christopher Hanrahan; Kenneth Boucher; Paul E Christian; Regan I Butterfield; Kathryn A Morton
Journal:  Clin Nucl Med       Date:  2012-12       Impact factor: 7.794

4.  Upper extremity deep vein thrombosis.

Authors:  Sanjith Saseedharan; Sunil Bhargava
Journal:  Int J Crit Illn Inj Sci       Date:  2012-01

5.  Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis.

Authors:  Julia Humphries; James A Gossage; Bijan Modarai; Kevin G Burnand; Thomas H Sisson; Colin Murdoch; Alberto Smith
Journal:  J Vasc Surg       Date:  2009-08-22       Impact factor: 4.268

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.